DK2099796T3 - Aza-indolyl-forbindelser og fremgangsmåder for anvendelse - Google Patents
Aza-indolyl-forbindelser og fremgangsmåder for anvendelseInfo
- Publication number
- DK2099796T3 DK2099796T3 DK07854844.3T DK07854844T DK2099796T3 DK 2099796 T3 DK2099796 T3 DK 2099796T3 DK 07854844 T DK07854844 T DK 07854844T DK 2099796 T3 DK2099796 T3 DK 2099796T3
- Authority
- DK
- Denmark
- Prior art keywords
- aza
- methods
- indolyl compounds
- indolyl
- compounds
- Prior art date
Links
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86805506P | 2006-11-30 | 2006-11-30 | |
| US91762007P | 2007-05-11 | 2007-05-11 | |
| US94474307P | 2007-06-18 | 2007-06-18 | |
| PCT/US2007/085962 WO2008067481A1 (en) | 2006-11-30 | 2007-11-29 | Aza-indolyl compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2099796T3 true DK2099796T3 (da) | 2011-09-05 |
Family
ID=39169665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07854844.3T DK2099796T3 (da) | 2006-11-30 | 2007-11-29 | Aza-indolyl-forbindelser og fremgangsmåder for anvendelse |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7855216B2 (OSRAM) |
| EP (1) | EP2099796B1 (OSRAM) |
| JP (1) | JP5211063B2 (OSRAM) |
| AR (1) | AR064031A1 (OSRAM) |
| AT (1) | ATE511509T1 (OSRAM) |
| AU (1) | AU2007325123B2 (OSRAM) |
| CA (1) | CA2672327A1 (OSRAM) |
| CL (1) | CL2007003444A1 (OSRAM) |
| DK (1) | DK2099796T3 (OSRAM) |
| PE (1) | PE20081354A1 (OSRAM) |
| PL (1) | PL2099796T3 (OSRAM) |
| PT (1) | PT2099796E (OSRAM) |
| TW (1) | TW200829586A (OSRAM) |
| WO (1) | WO2008067481A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011526267A (ja) * | 2008-07-03 | 2011-10-06 | バイエル ファーマ アクチエンゲゼルシャフト | 化合物および放射性医薬品の製造方法 |
| WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
| WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳－法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
| KR101826382B1 (ko) | 2010-07-30 | 2018-02-06 | 온코세라피 사이언스 가부시키가이샤 | 퀴놀린 유도체 및 이를 함유하는 ｍｅｌｋ 억제제 |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| TW201414734A (zh) | 2012-07-10 | 2014-04-16 | Takeda Pharmaceutical | 氮雜吲哚衍生物 |
| US20150265679A1 (en) | 2012-11-02 | 2015-09-24 | The United States Of America, As Represented By Secretary, Department Of Health And Human Services | Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor |
| UA111925C2 (uk) | 2012-12-11 | 2016-06-24 | Федора Фармасьютікалз Інк. | БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| AU2017249229A1 (en) | 2016-04-15 | 2018-10-04 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| US11161845B2 (en) * | 2017-05-19 | 2021-11-02 | Nflection Therapeutics, Inc. | Pyrrolopyridine-aniline compounds for treatment of dermal disorders |
| CA3063535A1 (en) | 2017-05-19 | 2018-11-22 | Nflection Therapeutics, Inc. | Fused heteroaromatic-aniline compounds for treatment of dermal disorders |
| WO2019051296A1 (en) | 2017-09-08 | 2019-03-14 | Genentech, Inc. | DIAGNOSTIC AND THERAPEUTIC METHODS OF CANCER |
| WO2019158579A1 (en) | 2018-02-13 | 2019-08-22 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| WO2020106305A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Thienyl-aniline compounds for treatment of dermal disorders |
| JP7406264B2 (ja) | 2018-11-20 | 2023-12-27 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置のためのシアノアリール－アニリン化合物 |
| US12378240B2 (en) | 2018-11-20 | 2025-08-05 | Nflection Therapeutics, Inc. | Naphthyridinone-aniline compounds for treatment of dermal disorders |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| CA3238962A1 (en) | 2021-11-23 | 2023-06-01 | Nflection Therapeutics, Inc. | Formulations of pyrrolopyridine-aniline compounds |
| IL313821A (en) * | 2022-01-28 | 2024-08-01 | Insilico Medicine Ip Ltd | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) inhibitors and their uses |
| US20250171451A1 (en) * | 2022-03-04 | 2025-05-29 | Samjin Pharmaceutical Co., Ltd. | Novel heterocyclic compound and pharmaceutical composition comprising same |
| WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
| WO2025026383A1 (en) * | 2023-08-02 | 2025-02-06 | Insilico Medicine Ip Limited | Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof |
| KR20250067072A (ko) * | 2023-11-07 | 2025-05-14 | 보로노이 주식회사 | 헤테로아릴 유도체 화합물 및 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2003091214A1 (en) * | 2002-04-23 | 2003-11-06 | Aventis Pharmaceuticals Inc. | 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo |
| US6929411B2 (en) * | 2003-09-03 | 2005-08-16 | Hewlett-Packard Development Company, L.P. | Selectable control of raster image processor |
| GB0412914D0 (en) * | 2004-06-10 | 2004-07-14 | Oxagen Ltd | Compounds |
| AR049300A1 (es) * | 2004-06-15 | 2006-07-12 | Schering Corp | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos |
| US7598259B2 (en) * | 2004-06-15 | 2009-10-06 | Schering Corporation | mGluR1 antagonists as therapeutic agents |
| DE102005013621A1 (de) * | 2005-03-24 | 2006-09-28 | Curacyte Discovery Gmbh | Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika |
| AR070127A1 (es) * | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
-
2007
- 2007-11-29 JP JP2009539490A patent/JP5211063B2/ja not_active Expired - Fee Related
- 2007-11-29 PE PE2007001679A patent/PE20081354A1/es not_active Application Discontinuation
- 2007-11-29 AT AT07854844T patent/ATE511509T1/de active
- 2007-11-29 AR ARP070105307A patent/AR064031A1/es unknown
- 2007-11-29 CL CL200703444A patent/CL2007003444A1/es unknown
- 2007-11-29 WO PCT/US2007/085962 patent/WO2008067481A1/en not_active Ceased
- 2007-11-29 AU AU2007325123A patent/AU2007325123B2/en not_active Ceased
- 2007-11-29 CA CA002672327A patent/CA2672327A1/en not_active Abandoned
- 2007-11-29 PL PL07854844T patent/PL2099796T3/pl unknown
- 2007-11-29 US US11/947,656 patent/US7855216B2/en not_active Expired - Fee Related
- 2007-11-29 PT PT07854844T patent/PT2099796E/pt unknown
- 2007-11-29 EP EP07854844A patent/EP2099796B1/en active Active
- 2007-11-29 DK DK07854844.3T patent/DK2099796T3/da active
- 2007-11-29 TW TW096145474A patent/TW200829586A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007325123B2 (en) | 2012-12-13 |
| CA2672327A1 (en) | 2008-06-05 |
| JP5211063B2 (ja) | 2013-06-12 |
| EP2099796A1 (en) | 2009-09-16 |
| PL2099796T3 (pl) | 2011-10-31 |
| PE20081354A1 (es) | 2008-11-14 |
| US20080242655A1 (en) | 2008-10-02 |
| TW200829586A (en) | 2008-07-16 |
| AU2007325123A1 (en) | 2008-06-05 |
| CL2007003444A1 (es) | 2008-06-27 |
| EP2099796B1 (en) | 2011-06-01 |
| US7855216B2 (en) | 2010-12-21 |
| HK1135099A1 (en) | 2010-05-28 |
| PT2099796E (pt) | 2011-09-06 |
| ATE511509T1 (de) | 2011-06-15 |
| AR064031A1 (es) | 2009-03-04 |
| JP2010511626A (ja) | 2010-04-15 |
| WO2008067481A1 (en) | 2008-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2099796T3 (da) | Aza-indolyl-forbindelser og fremgangsmåder for anvendelse | |
| ATE531720T1 (de) | Aza-benzofuranylverbindungen und anwendungsverfahren dafür | |
| EP2094085A4 (en) | ANTI-CHOLESTEROLMIC COMPOUNDS AND METHODS OF USE | |
| DK1940839T3 (da) | Pyridopyrimidione Inhibitors of P13Ka | |
| DK1924577T3 (da) | Substituerede benzimidazoler og fremgangsmåder til fremstilling | |
| DK2001556T3 (da) | Thioninium-forbindelser og anvendelse deraf | |
| CY2014012I2 (el) | Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης | |
| ZA200802822B (en) | Raf inhibitor compounds and methods of use thereof | |
| ZA200710969B (en) | Raf inhibitor compounds and methods of use thereof | |
| NO345061B1 (no) | Anvendelse av DPP-IV inhibitorer | |
| DK1802872T3 (da) | Rörledning | |
| EP2023718A4 (en) | CREATINLIGATE COMPOUNDS AND APPLICATION METHOD THEREFOR | |
| ZA200802585B (en) | Pyridopyrimidinone inhibitors of Pl3Kα | |
| IL197060A0 (en) | Aza-benzothiophenyl compounds and methods of use | |
| DK2152748T3 (da) | Anti-Notch1-NRR-antistoffer og fremgangsmåder til anvendelse deraf | |
| HRP20150003T1 (xx) | Sastavi inhibitora dpp-iv | |
| DK2147315T3 (da) | Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf | |
| DK2118140T3 (da) | Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf | |
| DK2069467T3 (da) | Adskillende sammensætninger og fremgangsmåder til anvendelse | |
| DK2079485T3 (da) | Phenylpropionamidforbindelser og anvendelsen deraf | |
| DK3338790T3 (da) | Oligopeptid-forbindelser og anvendelser deraf | |
| EP2079544A4 (en) | ARSENIC ABSORBENT COMPOSITION AND METHODS OF USE | |
| ZA200808017B (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
| DK2107373T3 (da) | Analysechip og analysefremgangsmåde | |
| IL185309A0 (en) | Isoqunoline compounds and methods of use thereof |